Respiratory Syncytial Virus Infections Pipeline Market Report 2021: Insights on Approx 50+ Companies & Respective Products – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Respiratory Syncytial Virus Infections – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This “Respiratory syncytial virus infections – Pipeline Insight, 2021” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Respiratory syncytial virus infections pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

The companies and academics are working to assess challenges and seek opportunities that could influence Respiratory syncytial virus infections R&D. The therapies under development are focused on novel approaches to treat/improve Respiratory syncytial virus infections.

Respiratory syncytial virus infections Emerging Drugs Chapters

This segment of the Respiratory syncytial virus infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Respiratory syncytial virus infections Emerging Drugs

GSK3844766A: GlaxoSmithKline

This candidate vaccine contains a recombinant subunit pre-fusion RSV antigen (RSVPreF3) combined with GSK’s proprietary AS01 adjuvant, which is also used in GSK’s shingles vaccine. Currently, it is in phase III of development stage for the treatment of Respiratory syncytial virus infections.

Nirsevimab (MEDI-8897): MedImmune

MEDI8897 is a monoclonal antibody (mAb) for the prevention of lower respiratory tract illness (LRTI) caused by respiratory syncytial virus (RSV), the most prevalent cause of LRTI among infants and young children. Currently, it is in phase III of development stage.

Sisunatovir: ReViral

Sisunatovir is an orally administered fusion inhibitor designed to block RSV replication by inhibiting RSV F-mediated fusion of RSV with the host cell. Preclinical tests showed sisunatovir to have an excellent toxicity profile with an attractive therapeutic index. In Phase 1 clinical studies, sisunatovir showed excellent exposure with no serious adverse events being reported.

In 2018, results from a Phase 2a challenge study in healthy adult volunteers were reported in which sisunatovir produced statistically significant reductions in viral load and clinical symptoms. ReViral has initiated two international multicentre Phase 2 clinical studies of sisunatovir in pediatric and adult high-risk patient populations

Respiratory syncytial virus infections: Therapeutic Assessment

This segment of the report provides insights about the different Respiratory syncytial virus infections drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Respiratory syncytial virus infections

There are approx. 50+ key companies which are developing the therapies for Respiratory syncytial virus infections. The companies which have their Respiratory syncytial virus infections drug candidates in the most advanced stage, i.e. phase III include, GlaxoSmithKline.

Phases

This report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Respiratory syncytial virus infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Respiratory syncytial virus infections: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Respiratory syncytial virus infections therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Respiratory syncytial virus infections drugs.

Respiratory syncytial virus infections Report Insights

• Respiratory syncytial virus infections Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Respiratory syncytial virus infections Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

• How many companies are developing Respiratory syncytial virus infections drugs?
• How many Respiratory syncytial virus infections drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Respiratory syncytial virus infections?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Respiratory syncytial virus infections therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Respiratory syncytial virus infections and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• GlaxoSmithKline
• MedImmune
• ReViral
• Pfizer
• Sanofi
• BioComo
• IMV
• Shionogi
• Aridis Pharmaceuticals
• ADMA Biologics
• Enanta Pharmaceuticals
• Merck Sharp & Dohme
• Janssen Research & Development
• Ark Biosciences
• BlueWillow Biologics
• Meissa Vaccines
• Alios BioPharma
• Codagenix
• Advance Vaccine Laboratories
• Bavarian Nordic
• ModernaTX, Inc.
• Virometix
• Airway Therapeutics LLC
• AlloVir Inc
• Anima Biotech Inc
• Aridis Pharmaceuticals Inc
• Atea Pharmaceuticals Inc
• Atriva Therapeutics
• Calder Biosciences Inc
• Cidara Therapeutics Inc
• Clover Biopharmaceuticals
• Curevac AG
• Enyo Pharma SA
• HanaVax Inc.
• Icosavax Inc
• IDBiologics Inc
• Pneumagen Ltd
• Riboscience LLC
• Signia Therapeutics

Key Products

• GSK3844766A
• Nirsevimab (MEDI-8897)
• Sisunatovir
• RSV F protein vaccine
• Novavax
• Combination seasonal influenza RSV nanoparticle vaccine
• NanoFlu/NVX CoV 2373/RSV
• RSVpreF
• SP 0125
• BC-0004
• GSK 3888550A
• DPX RSV Vaccine
• AR 201
• ASCENIV
• EDP 938
• MK 1654
• Rilematovir
• GSK 3003891A
• JNJ 64400141
• Ziresovir
• JNJ 64213175
• MV-012-968
• ALS-008176
• CodaVax-RSV
• BARS13
• MVA-BN-RSV
• mRNA-1345
• V-306
• ALVR106
• AR-201
• AT-889
• ATR-002
• IVX-121
• RBS-3149

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/2kxuq

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900